- Home
- ALNY vs HES Comparison
ALNY vs HES Comparison
Compare ALNY & HES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALNY
- HES
- Stock Information
- Founded
- ALNY 2002
- HES 1920
- Country
- ALNY United States
- HES United States
- Employees
- ALNY N/A
- HES N/A
- Industry
- ALNY Biotechnology: Pharmaceutical Preparations
- HES Integrated oil Companies
- Sector
- ALNY Health Care
- HES Energy
- Exchange
- ALNY Nasdaq
- HES Nasdaq
- Market Cap
- ALNY 35.0B
- HES 41.4B
- IPO Year
- ALNY 2004
- HES N/A
- Fundamental
- Price
- ALNY $234.56
- HES $130.64
- Analyst Decision
- ALNY Strong Buy
- HES Buy
- Analyst Count
- ALNY 24
- HES 10
- Target Price
- ALNY $322.39
- HES $166.86
- AVG Volume (30 Days)
- ALNY 1.3M
- HES 2.3M
- Earning Date
- ALNY 05-01-2025
- HES 04-30-2025
- Dividend Yield
- ALNY N/A
- HES 1.53%
- EPS Growth
- ALNY N/A
- HES 100.00
- EPS
- ALNY N/A
- HES 8.98
- Revenue
- ALNY $2,248,243,000.00
- HES $12,662,000,000.00
- Revenue This Year
- ALNY $31.17
- HES N/A
- Revenue Next Year
- ALNY $24.99
- HES $16.57
- P/E Ratio
- ALNY N/A
- HES $14.55
- Revenue Growth
- ALNY 22.97
- HES 22.99
- 52 Week Low
- ALNY $141.98
- HES $123.79
- 52 Week High
- ALNY $304.39
- HES $163.98
- Technical
- Relative Strength Index (RSI)
- ALNY 44.35
- HES 38.27
- Support Level
- ALNY $225.84
- HES $124.34
- Resistance Level
- ALNY $242.15
- HES $131.63
- Average True Range (ATR)
- ALNY 17.21
- HES 6.40
- MACD
- ALNY -2.15
- HES -1.95
- Stochastic Oscillator
- ALNY 42.35
- HES 16.87
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
About HES Hess Corporation
Hess is an independent oil and gas producer with key assets in the Bakken Shale, Guyana, the Gulf of Mexico, and Southeast Asia. At the end of 2023, the company reported net proved reserves of 1.4 billion barrels of oil equivalent. Net production averaged 391 thousand barrels of oil equivalent per day in 2023, at a ratio of 74% oil and natural gas liquids and 26% natural gas.